Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DXC007
- Development stage
- Phase 1
- Lead developer
- Hangzhou DAC Biotech
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
DXC007 is an antibody-drug conjugate (ADC) developed by Hangzhou DAC Biotech, targeting the myeloid cell surface antigen CD33. It is specifically designed for the treatment of relapsed or refractory acute myeloid leukemia (AML). The drug consists of a recombinant humanized anti-CD33 monoclonal antibody conjugated to Tub255, a potent tubulin inhibitor payload. Upon binding to CD33 on leukemic cells, the ADC is internalized, releasing Tub255 to disrupt microtubule assembly, which induces cell cycle arrest and apoptosis. DXC007 has entered Phase 1 clinical trials in China to evaluate its safety, tolerability, and pharmacokinetic profile in patients with AML.
02
Targets
CD33 (Myeloid cell surface antigen CD33)
Beyond the preview
Go deeper on DXC007.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DXC007.